Beyondspring Inc (NQ: BYSI )

9.750 USD -0.220 (-2.21%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2021 Add to My Watchlist

Price and Volume

Volume	103,977
Open	9.940
Bid (Size)	9.600 (10)
Ask (Size)	10.80 (10)
Prev. Close	9.970
Today's Range	9.700 - 9.940
52wk Range	9.240 - 17.81
Shares Outstanding	39,106,476
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

July 14, 2021

BeyondSpring to Participate in the William Blair Biotech Focus Conference

July 08, 2021

Performance

YTD	-19.82%	-19.82%
1 Month	-11.36%	-11.36%
3 Month	-8.19%	-8.19%
6 Month	-27.51%	-27.51%
1 Year	-18.68%	-18.68%

More News

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

June 17, 2021

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

June 16, 2021

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

June 11, 2021

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annua

June 10, 2021

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim

June 08, 2021

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induc

June 07, 2021

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with

June 04, 2021

BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

June 01, 2021

Analysts Predict 22% Upside For The Holdings of IWO

July 22, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.